To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.

NCT05223686 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG: Human CD19-CD22 Targeted T Cells Injection

Sponsor

Hrain Biotechnology Co., Ltd.

Collaborators

[object Object]